<DOC>
	<DOCNO>NCT01302249</DOCNO>
	<brief_summary>This double-masked , randomize , multi-center , active-controlled , crossover comparison addition AR-12286 timolol latanoprost treatment elevate intraocular pressure ( IOP ) .</brief_summary>
	<brief_title>AR-12286 Combination With Latanoprost</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>18 year age great . Diagnosis open angle glaucoma ( OAG ) ocular hypertension ( OHT ) . Currently use prostaglandin analogue ( monotherapy combination therapy ) O.U . ≥ 1 month time study entry ( first qualification visit ) study eye ( ) . Qualification Visit 1 ( Screening ) IOP 16:00 hr : PG monotherapy patient : ≥ 18 mm Hg ; Combination therapy patient : &gt; = 16 mm Hg . Qualification Visit 2 ( post latanoprost runin ) IOP ≥ 20 mm Hg 08:00 hr 10:00 hr , IOP ≥ 18 mm Hg 16:00 hr study eye ( ) . ( Note : combination therapy may include combination topical ocular hypotensive agent ) . Corrected visual acuity eye +1.0 logMAR good ETDRS eye ( equivalent 20/200 ) . Able willing give sign informed consent follow study instruction In either eye : Previously randomize treatment clinical study AR12286 . Intraocular pressure &gt; 36 mm Hg . History acute angleclosure glaucoma , close narrow angle upon gonioscopy Known hypersensitivity contraindication timolol maleate ophthalmic solution , component formulation ( benzalkonium chloride , etc . ) , topical anesthetic , include history conjunctival hyperemia topical latanoprost severity great 1 03 scale . Ocular trauma within past six month , ocular surgery laser treatment within past three month . Contact lens wear within 30 minute instillation study medication . PG monotherapy patient : Ocular hypotensive medication ( prostaglandin ) within 4 week Visit 0 ( Study entry , first qualification visit ) . Combination therapy patient : Ocular hypotensive medication ( prostaglandin current additional agent ) within 4 week Visit 0 ( Study entry , first qualification visit ) . Conjunctival hyperemia grade 2+ great Visit 1 . Any ocular medication within 4 week Visit 1 exception lubricate drop dry eye ( may use throughout study ) . Clinically significant ocular disease ( e.g . corneal edema , uveitis , severe keratoconjunctivitis sicca ) might interfere study , include glaucomatous damage severe treatment latanoprost two period 4 week judge safe ( e.g. , advance glaucomatous optic nerve head visual field loss ) . Any abnormality prevent reliable applanation tonometry either eye . In study eye ( ) : Glaucoma : pseudoexfoliation pigment dispersion component , history angle closure . Note : Previous laser peripheral iridotomy acceptable . Previous glaucoma intraocular surgery laser procedure . Refractive surgery ( e.g. , radial keratotomy , PRK , LASIK , etc. ) . Central corneal thickness great 600 µ . Systemic : Known bronchial asthma ( history current ) , severe chronic obstructive pulmonary disease , sinus bradycardia , second third degree atrioventricular block overt cardiac failure . Clinically significant abnormality laboratory test screen , recognize subject fasting time draw blood . Clinically significant systemic disease ( e.g. , uncontrolled diabetes , myasthenia gravis , hepatic , renal , cardiovascular endocrine disorder ) might interfere study . Participation investigational study within past 30 day . Changes systemic medication could substantial effect IOP 4 week prior screen , anticipate study . Women childbearing potential pregnant , nursing , plan pregnancy , use medically acceptable form birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Intraocular pressure</keyword>
	<keyword>Ocular hypertension</keyword>
</DOC>